Navigation Links
Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Date:7/17/2008

SOUTH SAN FRANCISCO, Calif., July 17 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has begun a Phase 2 clinical trial of Adlea(TM), the company's long-acting, site specific, non-opioid drug candidate for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

Adlea is currently in two pivotal Phase 3 trials in the U.S.: one in total knee replacement surgeries and one in bunionectomy surgeries. An additional Phase 2 Adlea trial is in progress in total hip replacement surgeries. These trials are among those intended to support an Adlea label indication for the management of acute pain following orthopedic surgery.

The Phase 2 arthroscopic shoulder surgery trial is being conducted in South Korea. Unlike the United States, where the procedure is often conducted on an outpatient basis, arthroscopic shoulder surgery patients in South Korea are routinely hospitalized for up to two days, thus allowing more extensive near-term follow-up.

"We believe Adlea holds promise for treating pain associated with a number of orthopedic surgical indications, and may reduce the need for other pain treatments such as opioids," said Michael L. Kranda, Anesiva's president and chief executive officer. "As we pursue a broad indication of management of post-surgical pain following orthopedic procedures, each specific procedure that we can evaluate will add to the breadth of available data for Adlea."

Arthroscopic surgery is performed through small incisions using an arthroscope, or camera, to visualize the inside of a joint. Through the incisions, a surgeon inserts a camera and small instruments to perform the procedure. According to the American Aca
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Defines Regulatory Pathway for Adlea with FDA
7. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
8. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...l., Nov. 9 Landauer, In... and environmental radiation monitoring services, ... in accordance with its long-term strategic priori...itions of Global Physics Solutions, Inc. (GPS) and..., President and CEO of Landauer. "These acquisitio...
(Date:11/9/2009)...KE, N.J., Nov. 9 Par Pha...nounced that it has extended the expiration date a...announced "Modified Dutch Auction" tender offer, i...to $65,000,000 aggregate principal amount, or up t...enior Subordinated Convertible Notes due 2010. ,...
(Date:11/9/2009)...d., Nov. 9 OriGene Technologies, I...in Sweden has adopted its VERIFY Tagged Antigen(TM...tlas program. This program is funded by the Knut a...plore the human proteome systematically using Anti...no-specific antibodies in a high throughput manner...
Breaking Medicine Technology:Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2Cellular Dynamics International Reprograms Blood Cells into Stem Cells 12932 1Cellular Dynamics International Reprograms Blood Cells into Stem Cells 12932 2Army study improves ability to predict drinking water needs 9158 1Army study improves ability to predict drinking water needs 9158 2Army study improves ability to predict drinking water needs 9158 3Army study improves ability to predict drinking water needs 9158 4Army study improves ability to predict drinking water needs 9158 5Concierge Medicine Takes Front Seat with Health Care Reform Uncertainty 51029 1Concierge Medicine Takes Front Seat with Health Care Reform Uncertainty 51029 2
...ss.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx,...inary results of,a phase 2 clinical trial studying...olone and the antidepressant paroxetine),and 3mg p...hritis,(RA). This trial served two important purpo...g of prednisolone alone (a very low dose),in RA an...
...tudy in Seventy Type 2 Diabetes Patients -, MONT...nc.,(TSX:CJB) today announced positive prelimina...nical study for the treatment of Type 2,diabetes...n-4.,Results from the study demonstrated that PC...and, when administered once-weekly at each,of th...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4
(Date:11/9/2009)...tions are age-related, researchers say , ...gery doesn,t appear to speed the progression of ag... a new study that challenges the belief that treat..., "Because both conditions are strongly age-relat... wrote Li Ming Dong, of Stony Brook University Sch...
(Date:11/9/2009)...od despite similar weight loss , , MONDA...-carbohydrate diet such as the popular Atkins prog...eople lose pounds over the course of a year. ,...lt in long-term improvement in mood, according to ...al Medicine . , People on both diets consumed r...
(Date:11/9/2009)...r visits, researchers add , , MONDAY, No...king more time consulting with adult patients, see...isits, a new study suggests. , "Patients spent ...g office visits in 2005 than they did almost a dec...tter care," said Dr. Lena M. Chen, from the Univer...
(Date:11/9/2009)...are often blamed for the increasing rates of child...ver finds that 80% of people think that parents sh... (PRWEB) November 9, 2009 -- If you thou...Australia’s obesity epidemic, think again. .... A recent survey commissioned for Fitness.com.au...
(Date:11/9/2009)...ered in April 2010, Provides First Responders with...bridge, MA (Vocus) November 9, 2009 -- When Stefan...t inspected a suspected mass grave at Dasht-e-Lei...am of experts to help interpret the scene. He knew...t step in securing evidence of a human rights viol...
Breaking Medicine News(10 mins):Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Doctors Spending More Time Now With Patients 2Health News:Doctors Spending More Time Now With Patients 3Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4
...at exercise could benefit both the young and the o...n that exercise not only helps the elderly in prot... function, thus reducing the risk of Upper Respira... and a frequent problem in the ambulatory setting....
...ich is a serious problem in people with cancer, AI...iver, lungs and heart. A recent study has found th...d in fruit flies, where it is involved in muscle d...ce. Mice that were genetically modified to lack th...
... Carolina in Chapel Hill that was published in the...suggests that two genes - C282Y and H63D, which ar...osis may also lead to an increased risk of develop...re matched with healthy controls. Researchers also...
...y in a hospital in Switzerland who investigated w...tory prostate cancer could be measured via changes...state cancer doubling time may be an auxiliary mar...efractory prostate cancer and bi-dimensionally mea...
...fts University in Boston has revealed that childre...ions displayed on television. They also use emotio...to make decisions. Donna Mumme, assistant pro...holder, a blue bumpy ball, and a yellow garden hos...
...otechnology outlines a new method developed by Mic...nes required for the production of industrial mole... in the company's ability to improve the propertie...mize a cell's metabolic potential to increase prod...
Other Medicine News:
ACCUTEST H. pylori Test (Whole Blood)
OraQuick Rapid HIV-1 Antibody Test
...ous Mononucleosis test is designed to detect the I...e blood. The QuickVue+ Infectious Mononucleosis as...ch give a greater sensitivity and specificity than...ythrocytes. QuickVue+ Infectious Mononucleosis is ...
...irst available point-of-care diagnostic test that ...nfluenza A and B. The test uses a unique substrate...ts viral replication by promoting the release of t...te is labeled with a chromagen. When influenza vir...
Medicine Products: